NovImmune: Novimmune's successor company receives milestone payment from Takeda

After the sale of its core asset to the Swedish biopharmaceutical company Sobi, Novimmune focusses on its bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience. The company announced the successful completion of the discovery phase and designation by Takeda of undisclosed bispecific antibodies as clinical development candidates.